
Dr. Li Xiaorong performed the first case with the SING IMT (smaller-incision new-generation implantable miniature telescope). It took place this month at the First Affiliated Hospital of Hainan Medical University Lecheng Hospital.
“The surgery went well as the device is designed for ease of central insertion and we will monitor our patient’s visual rehabilitation as they learn to use their new vision,” Li said in a news release. “Many older adults in China live with central blindness caused by late-stage, age-related macular degeneration and it impacts their quality of life. I look forward to offering this procedure to future patients as we advance through clinical trials and anticipate regulatory approval in the future.”
Samsara designed SING IMT to improve visual acuity and quality of life for people with late-stage age-related macular degeneration (AMD). It features a new, foldable haptic design that enables stability and centration during an outpatient procedure.
Additionally, the company designed it with a new Tsert SI delivery system, designed for consistent, predictable delivery. The overall system reduces the length of the surgical procedure, incision size and the number of sutures, speeding up recovery. Samsara says the device helps patients see things at all distances, stationary and in locomotion. Users can perform multiple activities in ways similar to natural vision.
”At Samsara Vision, we are rapidly developing a global network of providers, researchers, health systems, and advocates who are introducing our novel technology to people living with non-preventable blindness caused by late-stage AMD,” said Thomas Ruggia, president and CEO of Samsara Vision. “Our goal is for the SING IMT to be the standard of care for people who advance to late-stage AMD and we’re motivated by hearing the stories of patients resuming the activities they love. We congratulate Prof. Li and thank our partners at Lensheng Medical for their commitment to advancing our presence in China.”